Structure Therapeutics Inc.

We are a clinical-stage global biopharmaceutical company developing new oral small molecule drugs to treat various chronic diseases where current treatments are insufficient. Our technology platform uses structure-based drug discovery and computational chemistry to find and develop small molecule drugs that target G-protein coupled receptors (GPCRs). These receptors control many different body processes, and about one-third of all marketed medicines target GPCR-related pathways for conditions like metabolic, cardiovascular, and pulmonary disorders. Our most advanced drug candidate is aleniglipron (also known as GSBR-1290), an oral small molecule that activates the glucagon-like-peptide-1 receptor (GLP-1R). It is currently in five ongoing clinical studies for treating obesity, overweight, and related conditions. We also have two oral small molecule amylin receptor activators: ACCG-2671, which is in Phase 1 clinical development, and ACCG-3535, which is our second amylin development candidate. Our obesity pipeline also includes several preclinical small molecules targeting glucose-dependent insulinotropic polypeptide and glucagon receptors. These programs could be developed as single treatments or in fixed-dose combinations with our GLP-1 or amylin candidates. These combinations could address diseases beyond obesity, such as type 2 diabetes mellitus (T2DM), heart failure, sleep apnea, chronic kidney disease, osteoarthritis, metabolic dysfunction-associated steatotic liver disease (MASH), and potentially addiction, Parkinson's disease, and Alzheimer's disease. As oral small molecules, our candidates may be more accessible than biologic and peptide therapies, potentially offering different efficacy and safety, and are more scalable to manufacture for global demand.